<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharma Articles - Insights &amp; Trends | World Pharma Today</title>
	<atom:link href="https://www.worldpharmatoday.com/articles/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Tue, 08 Sep 2026 06:37:19 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1</generator>

<image>
	<url>https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg</url>
	<title>Pharma Articles - Insights &amp; Trends | World Pharma Today</title>
	<link>https://www.worldpharmatoday.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Beyond Market Access: Operational Regulatory Readiness Has Become the Real Gateway to Europe&#8217;s Pharmaceutical Market</title>
		<link>https://www.worldpharmatoday.com/articles/beyond-market-access-operational-regulatory-readiness-has-become-the-real-gateway-to-europes-pharmaceutical-market/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 07 Sep 2026 13:01:56 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/beyond-market-access-operational-regulatory-readiness-has-become-the-real-gateway-to-europes-pharmaceutical-market/</guid>

					<description><![CDATA[<p>Over the past two decades, the global pharmaceutical industry’s geography has changed profoundly: India’s pharmaceutical sector has evolved from a low-cost manufacturing base into a globally competitive industry capable of supplying regulated markets. China remains structurally critical, above all for APIs and key starting materials. South Korea is moving rapidly up the pharmaceutical value chain, [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/articles/beyond-market-access-operational-regulatory-readiness-has-become-the-real-gateway-to-europes-pharmaceutical-market/">Beyond Market Access: Operational Regulatory Readiness Has Become the Real Gateway to Europe’s Pharmaceutical Market</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Why the fastest route to low-GWP pMDIs requires more than a new propellant</title>
		<link>https://www.worldpharmatoday.com/articles/why-the-fastest-route-to-low-gwp-pmdis-requires-more-than-a-new-propellant/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 27 Aug 2026 10:02:56 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/why-the-fastest-route-to-low-gwp-pmdis-requires-more-than-a-new-propellant/</guid>

					<description><![CDATA[<p>Opinion by Darren Bromley-Davenport, Technical Manager at Orbia Fluor &#38; Energy Materials The transition to low-global warming potential (GWP) pressurised metered-dose inhalers (pMDIs) is now well underway. In recent years, significant progress has been made in identifying alternative propellants capable of reducing the environmental impact of pMDIs while maintaining the performance patients rely on. Among [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/articles/why-the-fastest-route-to-low-gwp-pmdis-requires-more-than-a-new-propellant/">Why the fastest route to low-GWP pMDIs requires more than a new propellant</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Why More Data Doesn&#8217;t Automatically Mean Better AI in Drug Discovery</title>
		<link>https://www.worldpharmatoday.com/articles/why-more-data-doesnt-automatically-mean-better-ai-in-drug-discovery/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 17 Aug 2026 07:18:26 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[Doses]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/why-more-data-doesnt-automatically-mean-better-ai-in-drug-discovery/</guid>

					<description><![CDATA[<p>When DeciBio asked nine senior pharma executives what was holding back AI adoption in R&#38;D, the answer wasn&#8217;t algorithms or compute. Three of the top four barriers they named were data problems, and low-quality data was cited by every single one of them. Every AI drug discovery pitch deck has a slide about proprietary data. [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/articles/why-more-data-doesnt-automatically-mean-better-ai-in-drug-discovery/">Why More Data Doesn’t Automatically Mean Better AI in Drug Discovery</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Beyond the Purity Percentage</title>
		<link>https://www.worldpharmatoday.com/articles/beyond-the-purity-percentage/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 06 Aug 2026 08:06:15 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/beyond-the-purity-percentage/</guid>

					<description><![CDATA[<p>How pharmaceutical and life-science R&#38;D teams can qualify high-purity specialty inorganic salts using rubidium chloride and rubidium carbonate to illustrate the importance of impurity profiles, analytical evidence, packaging and supplier consistency. Rubidium Carbonate Rubidium Chloride Qualification at a glance Focus: Impurity profile, evidence, consistency and control Use cases: Pharma, life science, diagnostics and formulation R&#38;D [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/articles/beyond-the-purity-percentage/">Beyond the Purity Percentage</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>The Engine of Cell Therapy Success: Why Analytical Development Determines Whether Promising Cell Therapies Reach Patients</title>
		<link>https://www.worldpharmatoday.com/research-insight/the-engine-of-cell-therapy-success-why-analytical-development-determines-whether-promising-cell-therapies-reach-patients/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 12 Jun 2026 09:57:32 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Research Insight]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/the-engine-of-cell-therapy-success-why-analytical-development-determines-whether-promising-cell-therapies-reach-patients/</guid>

					<description><![CDATA[<p>How advanced analytical methods, potency assays, and immune profiling are shaping the future of cancer cell therapies Cell therapies have transformed the treatment landscape for patients with cancer and other serious diseases. Innovations such as CAR-T cell therapies have demonstrated remarkable clinical success, offering new treatment options for patients with limited alternatives. While much of [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/research-insight/the-engine-of-cell-therapy-success-why-analytical-development-determines-whether-promising-cell-therapies-reach-patients/">The Engine of Cell Therapy Success: Why Analytical Development Determines Whether Promising Cell Therapies Reach Patients</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Stevanato Group and Syntegon Join Forces to Drive Innovation</title>
		<link>https://www.worldpharmatoday.com/articles/stevanato-group-and-syntegon-join-forces-to-drive-innovation/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 02 Jun 2026 13:27:06 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/stevanato-group-and-syntegon-join-forces-to-drive-innovation/</guid>

					<description><![CDATA[<p>Quality first: advanced manufacturing process for EZ-fill® cartridges The development of GLP-1 drugs has revolutionized the treatment of diabetes and obesity – and is a catalyst for breaking new grounds in ready-to-use cartridge manufacturing. Primary packaging provider Stevanato Group has teamed up with equipment supplier Syntegon to develop an advanced manufacturing process for Stevanato Group’s [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/articles/stevanato-group-and-syntegon-join-forces-to-drive-innovation/">Stevanato Group and Syntegon Join Forces to Drive Innovation</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Move Beyond Visibility: Why Cold Chain Orchestration is Now Essential for Thermal Assurance</title>
		<link>https://www.worldpharmatoday.com/articles/move-beyond-visibility-why-cold-chain-orchestration-is-now-essential-for-thermal-assurance/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 07 May 2026 12:00:58 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/move-beyond-visibility-why-cold-chain-orchestration-is-now-essential-for-thermal-assurance/</guid>

					<description><![CDATA[<p>As life sciences supply chains become more volatile, real-time visibility is increasingly the baseline for operational excellence. The next frontier is orchestration: turning fragmented signals into decisions that prevent excursions, reduce waste, and protect patients.  Sam Durham, Product Manager &#8211; Digital Solutions &#38; Services at Cold Chain Technologies, explains the role of digital technology in [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/articles/move-beyond-visibility-why-cold-chain-orchestration-is-now-essential-for-thermal-assurance/">Move Beyond Visibility: Why Cold Chain Orchestration is Now Essential for Thermal Assurance</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Speed in complex drug development is the late-phase outcome of early-phase decisions</title>
		<link>https://www.worldpharmatoday.com/articles/speed-in-complex-drug-development-is-the-late-phase-outcome-of-early-phase-decisions/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 17 Apr 2026 13:50:20 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/speed-in-complex-drug-development-is-the-late-phase-outcome-of-early-phase-decisions/</guid>

					<description><![CDATA[<p>Late-stage development is where timelines tighten, complexity increases, and the demand for speed becomes most visible. Execution is often treated as the lever—compressed timelines, parallel workstreams, faster decision-making. But speed is rarely created at that stage. It is shaped earlier, through decisions made when flexibility is still high and the cost of change is lower. [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/articles/speed-in-complex-drug-development-is-the-late-phase-outcome-of-early-phase-decisions/">Speed in complex drug development is the late-phase outcome of early-phase decisions</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>The Evolution of Field Execution in Specialty Pharma: From Coverage to Engagement</title>
		<link>https://www.worldpharmatoday.com/articles/the-evolution-of-field-execution-in-specialty-pharma-from-coverage-to-engagement/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 06 Apr 2026 08:17:20 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[Big Pharma]]></category>
		<category><![CDATA[Biopharmaceutical Development]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/the-evolution-of-field-execution-in-specialty-pharma-from-coverage-to-engagement/</guid>

					<description><![CDATA[<p>Why Field Execution Must Evolve Field execution — how pharma companies organize, direct, and deliver commercial and medical interactions with healthcare professionals (HCPs), prescribers, and institutional decision-makers (collectively, &#8220;customers&#8221;) — is a major contributor to commercial success. Accordingly, over the past decade, companies have invested heavily in sales force effectiveness, key account management, omnichannel strategies, [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/articles/the-evolution-of-field-execution-in-specialty-pharma-from-coverage-to-engagement/">The Evolution of Field Execution in Specialty Pharma: From Coverage to Engagement</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>4 Critical Peel Testing Parameters for Pharmaceutical Blister Packaging</title>
		<link>https://www.worldpharmatoday.com/packaging-labelling/4-critical-peel-testing-parameters-for-pharmaceutical-blister-packaging/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 03 Apr 2026 09:38:31 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[Packaging & Labelling]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/4-critical-peel-testing-parameters-for-pharmaceutical-blister-packaging/</guid>

					<description><![CDATA[<p>A blister pack may seem like a simple enough concept until you’re trying to prove that it will open cleanly every time. Peel testing turns each peel into data so you can protect dose integrity, support and child resistance and avoid line surprises. What Peel Testing Measures Peel testing measures the force required to separate [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/packaging-labelling/4-critical-peel-testing-parameters-for-pharmaceutical-blister-packaging/">4 Critical Peel Testing Parameters for Pharmaceutical Blister Packaging</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
